Author/Editor     Korošec, Peter
Title     Ugotavljanje in spremljanje odpornosti proti citostatikom pri drobnoceličnem pljučnem raku s pretočnim citometrom ter možne povezave z uspešnostjo zdravljenja
Translated title     Flow cytometry for detection of multidrug resistance in small cell lung cancer patients, and possible correlations with theapeutic efficacy
Type     članek
Source     Endoskopska revija
Vol. and No.     Letnik 7, št. 18
Publication year     2002
Volume     str. 58-62
Language     slo
Abstract     The aim of the study was to investigate the expression of multidrug resistance (MDR) associated proteins (P-glycoprotein, MRP, LRP and DNA topoisomerase II-alpha) and the level of functional dye efflux, as well as the apoptosis in the primary and dislocated tumor cells of the small cell lung cancer (SCLC) patients using flow cytometry. In addition, clinical response to the therapy with cisplatin and etoposide will be studied, as well as the prognostic value of MDR markers. Increased multidrug resistance is expected to be predictive of lower response rate. The SCLC patients with a high response at the inititation of treatment are expected to show low and equally distributed expression of MDR markers. However, as a short-term SCLC sensitivity very often results in relapse, a considerably increased expression of P-gp and MRP is to be anticipated, along with changes in the dye efflux and expression of the topoisomerase II-alpha.
Summary     Namen naše študije je s pretočnim citometrom ugotavljati in spremljati prisotnost različnih MDR (ang. Multidrug Resistance) proteinov (P-glikoproteina, MRP, LRP in topoizomeraze II-alfa) in fenotipskih lastnosti MDR (funkcionalni testi raven izvenceličnega transporta) ter raven apoptoze v tumorskih celicah primarnega tumorja in v zasevkih (predvsem v mediastinalnih bezgavkah) pri bolnikih z drobnoceličnim pljučnim rakom. Spremljali bomo klinični odgovor na kombinirano zdravljenje s citostatiki (cisplatin, etopozid) pri bolnikih z MDR-pozitivnimi in pri bolnikih z MDR-negativnimi tumorskimi celicami ter skušali ugotoviti prognostični pomen MDR-označevalcev. Menimo, da bo klinični odgovor pri bolnikih z MDR-pozitivnimi celicami slabši. Predvidevamo, da bodo imeli responderji z drobnoceličnim rakom na začetku zdravljenja s citostatiki nizko ekspresijo MDR-proteinov in da bo v rakavih celicah primarnega tumorja in v oddaljenih zasevkih raven markerjev enaka. Pričakujemo, da se bo ob relapsu v tumorskih celicah povečala ekspresija P-gp in MRP-proteinov, kar bodo verjetno spremljali tudi funkcionalno izrazitejši MDR-fenotipi rakavih celic in možna spremenjena ekspresija topoizomeraze II-alfa.
Descriptors     LUNG NEOPLASMS
CARCINOMA, SMALL CELL
ANTINEOPLASTIC AGENTS
DRUG RESISTANCE, MULTIPLE
FLOW CYTOMETRY
P-GLYCOPROTEIN
CISPLATIN
ETOPOSIDE
APOPTOSIS
DNA TOPOISOMERASE (ATP-HYDROLYSING)